Compare BridgeBio Pharma Inc (BBIO) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Blackrock Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Blackrock Inc trades at $1,148.83 (market cap $175.22B). The key difference: Blackrock Inc is far larger — about 10.5× BridgeBio Pharma Inc's market cap, and Blackrock Inc pays a 2.03% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | BLK | |
|---|---|---|
Market Cap | $16.61B | $175.22B |
Sector | Health | Financials |
52-Week High | $90.17 | $1.20K |
52-Week Low | $47.29 | $922.90 |
Enterprise Value | $18.16B | $176.32B |
Volume | — | 641,547 |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BlackRock (BLK) trades at $1,136.39, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $20.4B in 2024 to $24.2B in 2025, though net income margin compressed to 22.93%. Recent earnings beats and a 78.79% analyst buy rating support positive sentiment, while the stock trades near resistance at $1,144.
BLK presents a compelling investment case with consistent earnings outperformance and strong institutional support, though investors face risks from margin compression and legal scrutiny. The consensus price target of $1,350 suggests 18.8% upside potential, balanced by overbought technical indicators and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
